OxFORD Asset Management LLP lowered its stake in Radius Health, Inc. (NASDAQ:RDUS) by 83.7% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 30,080 shares of the biopharmaceutical company’s stock after selling 154,920 shares during the period. OxFORD Asset Management LLP owned approximately 0.07% of Radius Health worth $1,361,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently made changes to their positions in RDUS. BlackRock Inc. lifted its holdings in shares of Radius Health by 98,245.6% during the 1st quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock worth $101,679,000 after acquiring an additional 2,628,070 shares during the period. TimesSquare Capital Management LLC bought a new position in Radius Health in the 2nd quarter valued at approximately $25,589,000. BB Biotech AG lifted its stake in Radius Health by 11.0% in the 2nd quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock valued at $227,905,000 after purchasing an additional 498,400 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Radius Health by 67.8% in the 1st quarter. Bank of New York Mellon Corp now owns 444,049 shares of the biopharmaceutical company’s stock valued at $17,163,000 after purchasing an additional 179,471 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Radius Health by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock valued at $142,281,000 after purchasing an additional 135,071 shares during the last quarter.
Several equities analysts recently commented on RDUS shares. ValuEngine raised shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. BidaskClub raised shares of Radius Health from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Cantor Fitzgerald set a $58.00 price objective on shares of Radius Health and gave the company a “buy” rating in a research note on Sunday, July 23rd. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $38.00 price objective (up previously from $34.00) on shares of Radius Health in a research note on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Radius Health has an average rating of “Hold” and a consensus price target of $52.17.
Shares of Radius Health, Inc. (NASDAQ RDUS) opened at 36.77 on Thursday. The firm’s market capitalization is $1.60 billion. Radius Health, Inc. has a 12-month low of $31.58 and a 12-month high of $55.97. The firm has a 50-day moving average of $36.68 and a 200-day moving average of $38.72.
Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.23). The firm had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $1.96 million. During the same quarter in the previous year, the company earned ($1.01) earnings per share. Equities analysts anticipate that Radius Health, Inc. will post ($5.55) earnings per share for the current year.
In other news, major shareholder Growth N. V. Biotech acquired 150,000 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average cost of $34.97 per share, with a total value of $5,245,500.00. Following the transaction, the insider now owns 5,113,799 shares of the company’s stock, valued at approximately $178,829,551.03. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jose Carmona acquired 3,000 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The shares were purchased at an average cost of $32.83 per share, for a total transaction of $98,490.00. Following the completion of the transaction, the chief financial officer now directly owns 3,000 shares in the company, valued at approximately $98,490. The disclosure for this purchase can be found here. Insiders bought a total of 469,100 shares of company stock worth $16,328,382 over the last ninety days. Insiders own 15.00% of the company’s stock.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health, Inc. (NASDAQ:RDUS).
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.